Mainstay Capital Management LLC ADV Acquires 96,810 Shares of Becton Dickinson and Co (NYSE:BDX)

Mainstay Capital Management LLC ADV increased its holdings in shares of Becton Dickinson and Co (NYSE:BDX) by 8,211.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 97,989 shares of the medical instruments supplier’s stock after acquiring an additional 96,810 shares during the quarter. Mainstay Capital Management LLC ADV’s holdings in Becton Dickinson and were worth $611,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Almanack Investment Partners LLC. acquired a new position in shares of Becton Dickinson and in the 2nd quarter worth approximately $105,000. Bartlett & Co. LLC increased its stake in Becton Dickinson and by 2,900.0% during the 2nd quarter. Bartlett & Co. LLC now owns 450 shares of the medical instruments supplier’s stock worth $108,000 after buying an additional 435 shares during the period. BDO Wealth Advisors LLC increased its stake in Becton Dickinson and by 361.6% during the 1st quarter. BDO Wealth Advisors LLC now owns 577 shares of the medical instruments supplier’s stock worth $125,000 after buying an additional 452 shares during the period. Bridgeworth LLC purchased a new stake in Becton Dickinson and during the 2nd quarter worth approximately $131,000. Finally, Kaizen Advisory LLC increased its stake in Becton Dickinson and by 155.9% during the 2nd quarter. Kaizen Advisory LLC now owns 609 shares of the medical instruments supplier’s stock worth $146,000 after buying an additional 371 shares during the period. Institutional investors own 92.51% of the company’s stock.

NYSE:BDX traded up $4.13 during trading hours on Friday, reaching $242.62. 1,127,659 shares of the company’s stock were exchanged, compared to its average volume of 1,159,369. Becton Dickinson and Co has a 1-year low of $197.44 and a 1-year high of $265.87. The stock has a market cap of $69.83 billion, a P/E ratio of 25.59, a P/E/G ratio of 1.78 and a beta of 1.11. The company has a debt-to-equity ratio of 0.95, a current ratio of 1.23 and a quick ratio of 0.81.

Becton Dickinson and (NYSE:BDX) last released its earnings results on Thursday, August 2nd. The medical instruments supplier reported $2.91 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.86 by $0.05. The company had revenue of $4.28 billion during the quarter, compared to analysts’ expectations of $4.25 billion. Becton Dickinson and had a net margin of 4.73% and a return on equity of 14.16%. The business’s revenue was up 41.0% on a year-over-year basis. During the same quarter last year, the business earned $2.46 EPS. Sell-side analysts expect that Becton Dickinson and Co will post 11.01 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Friday, September 28th. Stockholders of record on Friday, September 7th were issued a $0.75 dividend. The ex-dividend date of this dividend was Thursday, September 6th. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.24%. Becton Dickinson and’s dividend payout ratio is presently 31.65%.

BDX has been the topic of several recent research reports. JPMorgan Chase & Co. raised shares of Becton Dickinson and from a “neutral” rating to an “overweight” rating and set a $175.00 price objective on the stock in a research report on Thursday, June 21st. ValuEngine raised shares of Becton Dickinson and from a “hold” rating to a “buy” rating in a research report on Tuesday, June 26th. KeyCorp reissued a “buy” rating and issued a $264.00 price objective on shares of Becton Dickinson and in a research report on Friday, August 3rd. Royal Bank of Canada reissued a “hold” rating and issued a $248.00 price objective on shares of Becton Dickinson and in a research report on Friday, August 3rd. Finally, Citigroup increased their target price on shares of Becton Dickinson and from $274.00 to $283.00 and gave the company a “buy” rating in a research report on Wednesday, August 8th. Four investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Becton Dickinson and presently has an average rating of “Buy” and an average price target of $253.79.

Becton Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

Recommended Story: Compound Annual Growth Rate (CAGR)

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply